Effect of baricitinib on functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDS

Kevin Pile; Bruce Kirkham; Elena Nikiphorou; Pedro López-Romero; Ilias Kouris; Thorsten Holzkaemper; Liliana Zaremba-Pechmann; Inmaculada de la Torre; Peter Taylor

Effect of baricitinib on functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDS

Kevin Pile
, Bruce Kirkham
, Elena Nikiphorou
, Pedro López-Romero
, Ilias Kouris
, Thorsten Holzkaemper
, Liliana Zaremba-Pechmann
, Inmaculada de la Torre
, Peter Taylor

Research output: Contribution to journal › Article › peer-review

Abstract

Abstract for the 2020 Australian Rheumatology Association 60th Annual Scientific Meeting, 16"19 May 2020. Aims: To assess if RA pts with moderate disease activity (MDA) benefit from improved physical function with BARI, approved for treatment of moderate-to-severe RA, to same extent as pts with high disease activity (HDA).

Original language	English
Pages (from-to)	16-16
Number of pages	1
Journal	Internal Medicine Journal
Volume	50
Issue number	Suppl. 2
Publication status	Published - 2020

Keywords

rheumatoid arthritis
treatment
baricitinib

Cite this

@article{53a3b1c80c294faeaa6798a2a9911427,

title = "Effect of baricitinib on functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDS",

abstract = "Abstract for the 2020 Australian Rheumatology Association 60th Annual Scientific Meeting, 16{"}19 May 2020. Aims: To assess if RA pts with moderate disease activity (MDA) benefit from improved physical function with BARI, approved for treatment of moderate-to-severe RA, to same extent as pts with high disease activity (HDA).",

keywords = "rheumatoid arthritis, treatment, baricitinib",

author = "Kevin Pile and Bruce Kirkham and Elena Nikiphorou and Pedro L{\'o}pez-Romero and Ilias Kouris and Thorsten Holzkaemper and Liliana Zaremba-Pechmann and Torre, \{Inmaculada de la\} and Peter Taylor",

year = "2020",

language = "English",

volume = "50",

pages = "16--16",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "John Wiley and Sons Inc",

number = "Suppl. 2",

}

TY - JOUR

T1 - Effect of baricitinib on functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDS

AU - Pile, Kevin

AU - Kirkham, Bruce

AU - Nikiphorou, Elena

AU - López-Romero, Pedro

AU - Kouris, Ilias

AU - Holzkaemper, Thorsten

AU - Zaremba-Pechmann, Liliana

AU - Torre, Inmaculada de la

AU - Taylor, Peter

PY - 2020

Y1 - 2020

N2 - Abstract for the 2020 Australian Rheumatology Association 60th Annual Scientific Meeting, 16"19 May 2020. Aims: To assess if RA pts with moderate disease activity (MDA) benefit from improved physical function with BARI, approved for treatment of moderate-to-severe RA, to same extent as pts with high disease activity (HDA).

AB - Abstract for the 2020 Australian Rheumatology Association 60th Annual Scientific Meeting, 16"19 May 2020. Aims: To assess if RA pts with moderate disease activity (MDA) benefit from improved physical function with BARI, approved for treatment of moderate-to-severe RA, to same extent as pts with high disease activity (HDA).

KW - rheumatoid arthritis

KW - treatment

KW - baricitinib

UR - https://hdl.handle.net/1959.7/uws:58233

M3 - Article

SN - 1444-0903

VL - 50

SP - 16

EP - 16

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - Suppl. 2

ER -

Effect of baricitinib on functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDS

Abstract

Keywords

Other files and links

Fingerprint

Cite this